Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis. 		Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties
Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.
Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

Monday, May 16, 2011

Urge Your Members to Support Family Caregivers

Last week, MS activists sent thousands of messages to Capitol Hill urging members of the House to support MS research funding. This week, continue that momentum and urge your Representative to support robust funding for the Lifespan Respite Care Program, another Society priority and program that helps people living with MS and their families.

Up to one quarter of individuals living with MS require long-term care services at some point during the course of the disease. Often, a family member steps into the role of primary caregiver, becoming some of our nation's 65 million caregivers who provide 80% of long-term care. Family caregivers are vital because they allow people living with MS to remain in the home, avoiding premature and costlier admission to nursing home facilities, but it can be a stressful job.

Respite care is short-term care that helps an individual or family take a break from the daily routine and stress of providing care. Enacted in 2006, the Lifespan Respite Care Program provides competitive grants to states to establish or enhance statewide lifespan respite programs, improve coordination, and improve respite access and quality so that family caregivers have the support they need. States are to serve families regardless of age or special need, making it a critical program for persons living with MS and their families--who are often ineligible for existing respite programs' age requirements.

The Lifespan Respite Care Program offers great promise to people living with MS and their families, but has been woefully underfunded. Representative Jim Langevin (RI-2) is circulating a "Dear Colleague" letter for members of the House to signal their support for robust appropriations for this important program. Contact your Representative today to inform him/her of the importance of the Lifespan Respite Care Program and urge him/her to sign on to Congressman Langevin's letter.

To keep future MS activism messages out of your junk folder, add the following address to your contacts or safe sender list: MSActionNetwork@nmss.org
Posted by Steve at Monday, May 16, 2011 0 comments

Wednesday, May 11, 2011

Your Rights as a Job Seeker or Employee with a Disability Teleconference

JOIN THE MOVEMENT

The NYC – Southern New York Chapter of the National MS Society is pleased to host Attorney Debra Wolf on Friday, May 13th from 2:00 – 4:00 pm. Ms. Wolf will be discussing your rights as job seekers or employees with a disability.

Attorney Debra Wolf will address questions such as:

What can an employer ask you on a job interview regarding your MS?
How and when to ask for an accommodation?
What are the laws regarding pre-employment medical testing
What constitutes discrimination and how to make a discrimination claim

This program is being offered to chapters in the region via teleconference. Please join us!

To register, please call:

NYC – Southern NY Chapter of the National MS Society
Barbara McKeon, MA, CRC, LMHC
212-453-3218
Posted by Steve at Wednesday, May 11, 2011 0 comments

Tuesday, May 10, 2011

Help Urgently Needed to Maintain MS Research Funding

Because of the hard work of MS activists across the country, approximately $17 million has been allocated to MS research under the Congressionally Directed Medical Research Programs (CDMRP) over the past four years. The CDMRP is a Department of Defense (DoD) program that is funded annually via the Defense Appropriations Act. It is important that you act now to ensure this funding stream for MS research is maintained!

We need your help to secure funding for MS research under the CDMRP. Ask your Representative to support a $15 million appropriation under the CDMRP that will help scientists to better understand the causes of MS and help find a cure. The large number of grant proposals submitted each year to the DoD for MS projects indicate that there is a clear need for more funding for MS research.

Because the timeline for requests has been condensed this year, Members of the House must submit their requests for Department of Defense appropriations by this Friday. Click here to contact your Representative today and ask them to show their support for people living with MS by signing onto a bipartisan Dear Colleague letter circulated by Representatives Burgess (TX-26) and Carnahan (MO-3), in addition to including the MS program in the CDMRP in their DoD appropriations request.

A similar letter will be circulated shortly in the Senate, so watch out for another legislative alert and opportunity to take action and support MS research!

To keep future MS activism messages out of your junk folder, add the following address to your contacts or safe sender list: MSActionNetwork@nmss.org
Posted by Steve at Tuesday, May 10, 2011 0 comments
Subscribe to: Posts (Atom)

About Me

My photo
North Grafton, Massachusetts, United States
Well-educated, disabled at this point with Multiple Sclerosis. I am very glad that I was able to do the things that I have been able to do over the years. had to change the picture, this one's more realistic.